Kenya Diabetic Retinopathy Drug Market 2023 Share, Size, Key Players, Revenue Analysis | Prudent Markets

The Kenya Diabetic Retinopathy Drug Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global Kenya Diabetic Retinopathy Drug market. This report explores all the key factors affecting the growth of the global Kenya Diabetic Retinopathy Drug market, including demand-supply scenario, pricing structure, profit margins, production, and value chain analysis.

Get PDF Sample Report Now! @ https://www.prudentmarkets.com/sample-request/141696/

Report Overview

The Diabetic Retinopathy drug market size in Kenya stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Diabetic Retinopathy (DR) is a major complication of diabetes, where damage to the retina is caused by micro-vascular damage to retinal vessels. If untreated, diabetic retinopathy leads to progressive vision loss and eventually blindness. The World Health Organization (WHO) estimates that the prevalence of diabetes in Kenya at 3.3% and predicts a rise to 4.5% by 2025. However, two-thirds of diabetics may be undiagnosed. DR has a negative impact on the quality of life. People with severe vision loss require additional health resources and endure reduced levels of physical, emotional and social well-being. Improved serum lipid and blood pressure control can also slow the progression of retinopathy, especially when initiated soon after the diagnosis of diabetes.

Market Drivers

The market is majorly driven by the increasing prevalence of diabetes and complications arising due to poor glycaemic control like Diabetic Retinopathy in Kenya. It is estimated that one in every three people with diabetes develop diabetic retinopathy. A study in Kenya found a prevalence of 35.9%.

The country is experiencing a rise in diabetes owing to demographic, nutritional and social changes such as urbanization.

The Development of new and improved drugs and advancement of technologies is expected to propel growth in the diabetic retinopathy drug market.

Increasing initiatives by Government of Kenya by implementation of National Diabetes Strategy and releasing guidelines for screening and management of Diabetic Retinopathy. A Diabetes Education Programme has also been implemented for healthcare staff.

However, there is a high unmet need for DR services in the country, which highlights the need to strengthen health systems.The barriers are lack of referral and inadequate knowledge of diabetes eye health.

To Know More About COVID-19 Impact On Kenya Diabetic Retinopathy Drug Market @ https://www.prudentmarkets.com/sample-request/141696/

Market Segmentation

By Treatment Type:

On the basis of treatment type, the market can be segmented into Anti-Vascular Endothelial Growth Factor Therapy, Intraocular Steroid Injection, Laser Surgery and Vitrectomy.

The anti-VEGF segment dominates the market owing to high applicability of these drugs in treatment of mild to moderate cases of non-proliferative DR and faster recovery. The major anti-VEGF agents currently used include Eylea, Avastin, Lucentis, and Macugen.

By Route of Administration:

On the basis of route of administration, the market can be segmented into Oral and Injectables.

Kenalog-40 (Bristol-Myers Squibb) is the most commonly used intraocular steroid and has been widely utilized as intravitreal injections since 2004 for the treatment of several retinal diseases.

By Distribution Channel:

On the basis of distribution channel, the market for diabetes drugs can be segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others.

Retail pharmacy segment holds the dominant share and is projected to high growth rates throughout the forecast period.

Major Players

The key players operating in the Diabetic Retinopathy Drug Market in Kenya are F. Hoffmann La- Roche AG, Pfizer, Inc. Bayer, Allergan PLC, Novartis AG, and others.

The most frequently used anti-VEGF drugs are Roche/Genentech's humanized antibodies Lucentis (ranibizumab) and Avastin (bevacizumab), and Bayer/Regeneron's fusion protein Eylea (aflibercept).

Kenalog-40 manufactured by Bristol-Myers Squibb is the most commonly used intraocular steroid.

Development of new drugs in leading to high growth in the diabetic retinopathy drug market. For instance, in April 2019, Novartis received approval for brolucizumab, an ophthalmic drug.

Highlighted Segments of Kenya Diabetic Retinopathy Drug Market:

Industry Overview: The first section of the research study covers an overview of the global Kenya Diabetic Retinopathy Drug Market, market status and prospects, and product range. In addition, it provides highlights of the major segments of the global Market, i.e., region, type, and application segments.

Competitive Analysis: This report illuminates important mergers and acquisitions, business expansion, product or service differences, market concentration, the competitive status of the global Kenya Diabetic Retinopathy Drug Market, and market size by player.

Company Profiles and Key Data: This section covers companies profiling the major players in the global Kenya Diabetic Retinopathy Drug Market based on the aforementioned revenue, products, business, and other factors.

Market size by type and application: In addition to providing an in-depth analysis of the industry size by type and application, this section provides research on top end users or consumers and potential applications.

Market Dynamics: This report covers the drivers, trends, and opportunities of the global Kenya Diabetic Retinopathy Drug Market. This section also includes Porter's analysis of five forces.

Findings and Conclusions: It provides strong recommendations for new as well as established players for securing a position of strength in the global Kenya Diabetic Retinopathy Drug Market.

Prudent Markets provides attractive discounts that fit your needs. Customization of the reports as per your requirement is also offered. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Speak To Our Analyst For A Discussion On The Above Findings, And Ask For A Discount On The Report @ https://www.prudentmarkets.com/discount-request/141696/

The report covers the competitive analysis of the market. As the demand is driven by a buyer's paying capacity and the rate of item development, the report shows the important regions that will direct growth. This section exclusively shares insight into the budget reports of big-league members of the market helping key players and new entrants understand the potential of investments in the Global Kenya Diabetic Retinopathy Drug Market. It can be better employed by both traditional and new players in the industry for complete know-how of the market.

Strategic Points Covered in Table of Content of Global Kenya Diabetic Retinopathy Drug Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Kenya Diabetic Retinopathy Drug market
Chapter 2: Exclusive Summary - the basic information of the Kenya Diabetic Retinopathy Drug Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the Kenya Diabetic Retinopathy Drug
Chapter 4: Presenting the Kenya Diabetic Retinopathy Drug Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User and Region/Country
Chapter 6: Evaluating the leading manufacturers of the Kenya Diabetic Retinopathy Drug market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions
Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Why should you purchase this report?

-Prudent Markets provides the vital historical and analysis data of global Kenya Diabetic Retinopathy Drug market.
-The report provides the entire assessment of the future market and altering market scenario or behavior.
-All the business decision could be backed through the several strategic business methodologies offered in the report.
-An extra edge in the competitive market could be obtained from this elaborative research report
-The report offers all the competitive landscape, growth drivers, applications, market dynamics, and other necessary details as well.

Purchase this report (Single User License) @ https://www.prudentmarkets.com/checkout/?id=141696&license_type=su

Free Customization on the basis of client requirements on Immediate purchase:
1- Free country-level breakdown of any 5 countries of your interest.
2- Competitive breakdown of segment revenue by market players.

Customization of the Report:
This report can be customized to meet the client's requirements. Please connect with our sales team (sales@prudentmarkets.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +91 83560 50278 || USA/Canada(Toll Free): 1800-601-6071 to share your research requirements.

Get ready to Recognize the pros and cons of the regulatory framework, local reforms, and its effect on the Industry. Understand how the Leaders in Intelligent Network are keeping themselves one stage forward with our most up-to-date survey analysis.

In conclusion, the Kenya Diabetic Retinopathy Drug Market report is a genuine source for accessing the research data which is projected to exponentially grow your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis and PESTLE analysis is also incorporated in the report.

Contact Us:
Allan Carter
Andheri, Maharashtra, 400102
USA/Canada(Toll Free): 1800-601-6071
Direct Line: +91 83560 50278
Mail: sales@prudentmarkets.com
Web: www.prudentmarkets.com

About Us:
We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy.

This release was published on openPR.